

Understanding NON-SMALL CELL LUNG CANCER (NSCLC)

A guide to biomarker testing for early-stage NSCLC



NeoGenomics' Early-stage NSCLC Panel is a test that looks at 4 biomarkers that can occur in the presence of non-small cell lung cancer. With this Panel, a sample of your cancer is sent to our lab, where the genes within your cancer cells are analyzed to help identify the presence of relevant genomic abnormalities.

Why do biomarker testing for early-stage non-small cell lung cancer?

- Panels that detect biomarkers can help identify potential treatment options. They may also lead to better outcomes. In fact, biomarker-informed adjuvant therapies significantly reduced mortality in patients with stage IB, II, or IIIA *EGFR*-mutated NSCLC disease.¹
- Immuno-oncology-based therapies may be beneficial for patients when cancer mutation and PD-L1 status is known.²
- Current guidelines recommend targeted chemotherapy and/or immunotherapy for early-stage NSCLC.

Why should I have the Early-stage NSCLC Panel done?

- In the US, lung cancer is the second most common cancer. It is the leading cause of cancer-related deaths.
- If lung cancer is found in an early stage, there is a higher likelihood of treatment with a positive outcome.
- Biomarker-assisted therapy selection can lead to longer disease-free survival.



Recent phase 3 clinical trial publications support the use of biomarker testing at Stage I-IIIa NSCLC

**Talk to your doctor about
NeoGenomics' Early-stage
NSCLC Panel today!**

1. Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected *EGFR*-mutated stage IB-IIIa non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. *J Clin Oncol.* 2023;41(10):1830-1840.

2. Tang Wen-Fang, Ye Hong-Yu, et al. Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone. *Frontiers in Oncology.* 2023; 13. DOI=10.3389/fonc.2023.1063183



How can the Early-stage NSCLC Panel help in my cancer journey?

Early-stage Non-Small Cell Lung Cancer Panel can help you and your care team by analyzing genes that are most relevant to therapy selection and prognosis for early-stage lung cancer using a panel of recognized biomarkers such as:

- **EGFR** – Is a protein on cells that helps them grow
- **ALK** – Helps the development of the nervous and gut systems
- **ROS1** – Gene receptor that is a regulator of normal cell processes
- **PD-L1** – Protein that is thought to be a co-inhibitory factor of the immune response



Talk to your care team about the Early-stage NSCLC Panel

Consider asking the following questions:

- How can the Early-stage NSCLC Panel be used in my treatment plan?
- When should I get tested?
- How often will I need to get tested?
- Will I need another tissue biopsy later in my treatment?
- What can the Early-stage NSCLC Panel results tell me about my cancer?
- What resources are available to me?

Still have questions? Write them here so you remember what to ask:

Contact a patient advocate today to learn more.

Email: patients@neogenomics.com
Phone: 866.776.5907, option 9



When will I get my results?

Once our lab receives your sample, testing takes 7 days. Your results will be provided to your care team as soon as they are available.

Have more questions about the Early-stage NSCLC Panel? Our Patient Advocate team is here to help.



Patient Portal



Patient Website



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 866.776.5907, option 9
Fax: 239.690.4237
Email: patients@neogenomics.com
neogenomics.com/patients